1 recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow Early-stage Mesothelioma: new trials by email Literature Review of Early-stage Mesothelioma trials Research Report on Early-stage Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma alrizomadlin - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-03-16 | 2026-03-17 | |
| Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma Decitabine/cedazuridine - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 15 | 2024-01-31 | 2026-10-16 |
Mesothelioma (2) · Mesothelioma, Malignant (2)
Adenoma (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Mesothelial (2) · Pleural Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
decitabine and cedazuridine drug combination (1)
National Cancer Institute (NCI) (2)
United States (2)